

# Active substances set

**Search phrase:** Liver cancer

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

## Liver cancer

| | | |
|---|---|---|
| **Regorafenib** | Regorafenib is indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. | NO REIMBURSEMENT<br>ESMO |
| **Cabozantinib** | Cabozantinib is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib. | NO REIMBURSEMENT<br>ESMO |
| **Ramucirumab** | Ramucirumab monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of ≥ 400 ng/ml and who have been previously treated with sorafenib. | NO REIMBURSEMENT<br>ESMO |
| **Ipilimumab** | Hepatocellular carcinoma (HCC) Ipilimumab in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma. | NO REIMBURSEMENT<br>ESMO |
| **Nivolumab** | Hepatocellular carcinoma (HCC) Nivolumab in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma. | NO REIMBURSEMENT<br>ESMO |

| | | |
|---|---|---|
| **Lenvatinib** | Lenvatinib as monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy. | REIMBURSEMENT WITH RESTRICTIONS<br>ESMO |
| **Atezolizumab** | Atezolizumab, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. | REIMBURSEMENT WITH RESTRICTIONS<br>ESMO |
| **Durvalumab** | Hepatocellular Carcinoma (HCC) Durvalumab as monotherapy is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). Durvalumab in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). | REIMBURSEMENT WITH RESTRICTIONS<br>ESMO |
| **Tremelimumab** | Tremelimumab in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). | FULL REIMBURSEMENT<br>ESMO |